Linus Jönsson

Summary

Affiliation: Stockholm Health Economics
Country: Sweden

Publications

  1. ncbi request reprint The potential economic consequences of cognitive improvement with losartan
    Linus Jönsson
    Department of Neuroscience, Occupational Therapy and Elderly Care Research NEUROTEC, Karolinska Institutet, Stockholm, Sweden
    Blood Press 11:46-52. 2002
  2. ncbi request reprint Determinants of costs of care for patients with Alzheimer's disease
    Linus Jönsson
    Division of Geriatric Epidemiology, The Neurotec Department, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 21:449-59. 2006
  3. ncbi request reprint Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden
    Linus Jönsson
    Stockholm Health Economics, Stockholm, Sweden
    Am J Geriatr Pharmacother 3:77-86. 2005
  4. ncbi request reprint Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL
    Linus Jönsson
    Neurotec, Section for Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Alzheimer Dis Assoc Disord 20:49-55. 2006
  5. ncbi request reprint Economic evidence in dementia: a review
    Linus Jönsson
    Stockholm Health Economics, Stockholm, Sweden
    Eur J Health Econ 5:S30-5. 2004
  6. ncbi request reprint [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial]
    Linus Jönsson
    Neurotec, Karolinska Institutet, Stockholm Health Economics, Centre for Health Economics, Stockholm School of Economics, Stockholm
    Ugeskr Laeger 165:4112-6. 2003
  7. ncbi request reprint Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease
    Linus Jönsson
    Department of Neuroscience, Occupational Therapy and Elderly Care Research NEUROTEC, Karolinska Institutet, Stockholm, Sweden
    Pharmacoeconomics 21:1025-37. 2003
  8. doi request reprint Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort
    Anders Gustavsson
    i3 Innovus, Klarabergsviadukten 90 Hus D, 111 64, Stockholm, Sweden
    Eur J Health Econ 13:561-8. 2012
  9. ncbi request reprint Health utilities in mild cognitive impairment and dementia: a population study in Sweden
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:649-55. 2007
  10. ncbi request reprint Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project--a population based study in Sweden
    Gunilla Nordberg
    Aging Research Center ARC, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:639-48. 2007

Collaborators

Detail Information

Publications29

  1. ncbi request reprint The potential economic consequences of cognitive improvement with losartan
    Linus Jönsson
    Department of Neuroscience, Occupational Therapy and Elderly Care Research NEUROTEC, Karolinska Institutet, Stockholm, Sweden
    Blood Press 11:46-52. 2002
    ..Thus, an improvement in cognitive function of the magnitude documented in the study of losartan vs hydrochlorothiazide, may translate into economic benefits beyond those expected in terms of blood pressure control...
  2. ncbi request reprint Determinants of costs of care for patients with Alzheimer's disease
    Linus Jönsson
    Division of Geriatric Epidemiology, The Neurotec Department, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 21:449-59. 2006
    ..Alzheimer's disease (AD), the most common cause of dementia, is a major cause of disability and care burden in the elderly. This study aims to estimate the costs of formal and informal care and identity determinants of care costs...
  3. ncbi request reprint Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden
    Linus Jönsson
    Stockholm Health Economics, Stockholm, Sweden
    Am J Geriatr Pharmacother 3:77-86. 2005
    ..Alzheimer's disease entails enormous costs for society and impairs quality of life for patients and caregivers...
  4. ncbi request reprint Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL
    Linus Jönsson
    Neurotec, Section for Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Alzheimer Dis Assoc Disord 20:49-55. 2006
    ..The study shows that the EuroQoL can be used to rate utilities in Alzheimer disease, but there are important differences between patient- and proxy-ratings...
  5. ncbi request reprint Economic evidence in dementia: a review
    Linus Jönsson
    Stockholm Health Economics, Stockholm, Sweden
    Eur J Health Econ 5:S30-5. 2004
  6. ncbi request reprint [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial]
    Linus Jönsson
    Neurotec, Karolinska Institutet, Stockholm Health Economics, Centre for Health Economics, Stockholm School of Economics, Stockholm
    Ugeskr Laeger 165:4112-6. 2003
  7. ncbi request reprint Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease
    Linus Jönsson
    Department of Neuroscience, Occupational Therapy and Elderly Care Research NEUROTEC, Karolinska Institutet, Stockholm, Sweden
    Pharmacoeconomics 21:1025-37. 2003
    ..However, these results should be viewed as preliminary, since we are still awaiting data from long-term follow-up studies. Also, the value of treatment for patients and caregivers in terms of QOL improvements has yet to be established...
  8. doi request reprint Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort
    Anders Gustavsson
    i3 Innovus, Klarabergsviadukten 90 Hus D, 111 64, Stockholm, Sweden
    Eur J Health Econ 13:561-8. 2012
    ..The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes...
  9. ncbi request reprint Health utilities in mild cognitive impairment and dementia: a population study in Sweden
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:649-55. 2007
    ..To collect new primary data on community-based health utilities (time trade-off values) in different stages of mild cognitive impairment and dementia from a general population sample...
  10. ncbi request reprint Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project--a population based study in Sweden
    Gunilla Nordberg
    Aging Research Center ARC, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:639-48. 2007
    ..The aging of the population has become a worldwide phenomenon. This leads to increased demand for services and with limited resources it is important to find a way to estimate how resources can be match to those with greatest need...
  11. ncbi request reprint Cost of hypoglycemia in patients with Type 2 diabetes in Sweden
    Linus Jönsson
    Stockholm Health Economics, Stockholm, Sweden
    Value Health 9:193-8. 2006
    ..The cost of hypoglycemia is, however, not well identified, particularly in patients with Type 2 diabetes. The purpose of this study was to assess the cost of hypoglycemia in Type 2 diabetes in Sweden...
  12. ncbi request reprint Cost of care for patients treated with lipid-lowering drugs
    Asa Carlsson
    Stockholm Health Economics, Stockholm, Sweden
    Pharmacoeconomics 22:25-35. 2004
    ..To investigate the relationship between attainment of treatment goals with lipid-lowering therapy and healthcare costs...
  13. doi request reprint Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease
    Niklas Bergvall
    i3 Innovus, Stockholm, Sweden
    Int Psychogeriatr 23:73-85. 2011
    ..However, the direct effect and relative importance of each disease severity measure remains unclear...
  14. doi request reprint Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients
    Anders Gustavsson
    Alzheimer s Disease Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
    Alzheimers Dement 7:318-27. 2011
    ..We aimed to identify what measures of disease severity are the most important predictors of societal costs of care and whether their relationship differs across countries...
  15. doi request reprint The cost of dementia in Europe: a review of the evidence, and methodological considerations
    Linus Jönsson
    i3 Innovus, Stockholm, Sweden
    Pharmacoeconomics 27:391-403. 2009
    ..Patient-level information on resource use is required to analyse determinants of care costs and predict the impact of therapeutic interventions. More data are needed to support future economic evaluations of therapies for AD...
  16. doi request reprint Application of Resource Utilization in Dementia (RUD) instrument in a global setting
    Anders Wimo
    KI Alzheimer Disease Research Centre, Karolinska Institutet, Sweden
    Alzheimers Dement 9:429-435.e17. 2013
    ..The aim of this study was to update the RUD to improve its face validity in Alzheimer's disease (AD) clinical research and its utility for health care resource allocation...
  17. doi request reprint Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies
    Anders Gustavsson
    i3 Innovus, Stockholm, Sweden
    Int J Geriatr Psychiatry 24:1072-8. 2009
    ..To assess the cost effectiveness of cholinesterase inhibitor (ChEI) treatment in patients with Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB)...
  18. doi request reprint The worldwide societal costs of dementia: Estimates for 2009
    Anders Wimo
    KI Alzheimer s Disease Research Center, Department of Neurobiology, Karolinska Institutet, Stockholm, Sweden
    Alzheimers Dement 6:98-103. 2010
    ..The purpose of this study was to update the previous estimate of the worldwide cost of dementia in 2005 to 2009...
  19. doi request reprint The worldwide economic impact of dementia 2010
    Anders Wimo
    KI Alzheimer Disease Research Centre, Karolinska Institutet, Stockholm, Sweden
    Alzheimers Dement 9:1-11.e3. 2013
    ..To acquire an understanding of the societal costs of dementia and how they affect families, health and social care services, and governments to improve the lives of people with dementia and their caregivers...
  20. doi request reprint Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants
    Anders Gustavsson
    Department of Neurobiology, Care Sciences and Society, KI Alzheimer s Disease Research Center, Karolinska Institutet, Stockholm, Sweden i3 Innovus, Stockholm, Sweden
    Alzheimers Dement 7:466-73. 2011
    ..Future clinical trial protocols can be optimized on the basis of the currently available data, including what are the key resources and how are they correlated to disease severity measures...
  21. doi request reprint Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer's disease
    Anders Gustavsson
    Department of Neurobiology, Care Sciences and Society, Alzheimeŕs Disease Research Center, Karolinska Institutet, Novum Plan 5, Stockholm, Sweden
    Int J Geriatr Psychiatry 25:622-32. 2010
    ..To estimate the value of informal care in Alzheimer's disease using contingent valuation...
  22. ncbi request reprint Burden of illness of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting
    Mattias Ekman
    Stockholm Health Economics, Stockholm, Sweden
    Spine (Phila Pa 1976) 30:1777-85. 2005
    ..Cross-sectional survey of patients with chronic low back pain in primary care setting...
  23. doi request reprint Cost of disorders of the brain in Europe 2010
    Anders Gustavsson
    OptumInsight, Stockholm, Sweden
    Eur Neuropsychopharmacol 21:718-79. 2011
    ..We therefore present much improved cost estimates. Our revised estimates also now include the new EU member states, and hence a population of 514 million people...
  24. doi request reprint The cost of diagnosing dementia in a community setting
    Erik Jedenius
    Alzheimer s Disease Research Centre, Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 25:476-82. 2010
    ..Further, in order to establish prerequisites for care and planning it is important to identify the cost of dementia diagnosis. This study aims to evaluate the cost of establishing a dementia diagnosis...
  25. ncbi request reprint Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
    Jonas Lundkvist
    Stockholm Health Economics, Vasagatan 38, 111 20, Stockholm, Sweden
    Breast Cancer Res Treat 102:289-99. 2007
    ....
  26. doi request reprint Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany
    Linus Jönsson
    i3 Innovus, Stockholm, Sweden
    Appl Health Econ Health Policy 8:317-25. 2010
    ..AF is associated with increased morbidity and mortality, e.g. from heart failure and thromboembolic events. Little data have previously been presented regarding the costs of treatment in patients with AF...
  27. doi request reprint Resource use and societal costs for Crohn's disease in Sweden
    Johan Mesterton
    i3 Innovus, Stockholm, Sweden
    Inflamm Bowel Dis 15:1882-90. 2009
    ..The usual onset of Crohn's disease (CD) is between 15 and 30 years of age, thus affecting people during their most economically productive period in life...
  28. ncbi request reprint Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice
    Peter Lindgren
    Stockholm Health Economics, Stockholm, Sweden
    Eur J Cardiovasc Prev Rehabil 12:530-4. 2005
    ..Our goal was to investigate if this translates to a higher risk of cardiovascular events in real clinical practice...
  29. ncbi request reprint The economic and quality of life impact of hypoglycemia
    Jonas Lundkvist
    Stockholm Health Economics, Stockholm, Sweden
    Eur J Health Econ 6:197-202. 2005
    ..9 and $14.1, respectively, for a 1-month period. The results indicate that hypoglycemia is common, and that a reduction in these symptoms, without reducing glycemic control, may improve patient well-being and possibly also reduce cost...